A Comparison Of Outcomes In Patients In New York Heart Association (NYHA) Class II Heart Failure When Treated With Eplerenone Or Placebo In Addition To Standard Heart Failure Medicines
Public ClinicalTrials.gov record NCT00232180. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
The Effect Of Eplerenone Versus Placebo On Cardiovascular Mortality And Heart Failure Hospitalization In Subjects With NYHA Class II Chronic Systolic Heart Failure
Study identification
- NCT ID
- NCT00232180
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Industry
- Enrollment
- 2,743 participants
Conditions and interventions
Conditions
Interventions
- Eplerenone Drug
Drug
Eligibility (public fields only)
- Age range
- 55 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 28, 2006
- Primary completion
- Apr 30, 2010
- Completion
- Dec 31, 2011
- Last update posted
- Dec 21, 2020
2006 – 2012
United States locations
- U.S. sites
- 51
- U.S. states
- 26
- U.S. cities
- 40
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pfizer Investigational Site | Phoenix | Arizona | 85008 | — |
| Pfizer Investigational Site | Loma Linda | California | 92354 | — |
| Pfizer Investigational Site | Merced | California | 95340 | — |
| Pfizer Investigational Site | Stockton | California | 95204 | — |
| Pfizer Investigational Site | Colorado Springs | Colorado | 80909 | — |
| Pfizer Investigational Site | Bridgeport | Connecticut | 06606 | — |
| Pfizer Investigational Site | Hartford | Connecticut | 06102 | — |
| Pfizer Investigational Site | Washington D.C. | District of Columbia | 20037 | — |
| Pfizer Investigational Site | Daytona Beach | Florida | 32117 | — |
| Pfizer Investigational Site | Gainesville | Florida | 32608 | — |
| Pfizer Investigational Site | Jupiter | Florida | 33458 | — |
| Pfizer Investigational Site | Melbourne | Florida | 32901 | — |
| Pfizer Investigational Site | Rockford | Illinois | 61107 | — |
| Pfizer Investigational Site | Indianapolis | Indiana | 46237 | — |
| Pfizer Investigational Site | Indianapolis | Indiana | 46260 | — |
| Pfizer Investigational Site | Louisville | Kentucky | 40202 | — |
| Pfizer Investigational Site | Louisville | Kentucky | 40205-3374 | — |
| Pfizer Investigational Site | Louisville | Kentucky | 40216 | — |
| Pfizer Investigational Site | Baton Rouge | Louisiana | 70808 | — |
| Pfizer Investigational Site | Bangor | Maine | 04401 | — |
| Pfizer Investigational Site | Annapolis | Maryland | 21401 | — |
| Pfizer Investigational Site | Columbia | Maryland | 21044-2914 | — |
| Pfizer Investigational Site | Boston | Massachusetts | 02118 | — |
| Pfizer Investigational Site | MN | Minnesota | 55101 | — |
| Pfizer Investigational Site | Minneapolis | Minnesota | 55417 | — |
| Pfizer Investigational Site | Tupelo | Mississippi | 38801-4600 | — |
| Pfizer Investigational Site | Tupelo | Mississippi | 38801 | — |
| Pfizer Investigational Site | Omaha | Nebraska | 68114 | — |
| Pfizer Investigational Site | Omaha | Nebraska | 68122 | — |
| Pfizer Investigational Site | Omaha | Nebraska | 68131 | — |
| Pfizer Investigational Site | Manchester | New Hampshire | 03102 | — |
| Pfizer Investigational Site | Albany | New York | 12208 | — |
| Pfizer Investigational Site | Rochester | New York | 14618 | — |
| Pfizer Investigational Site | Rochester | New York | 14642 | — |
| Pfizer Investigational Site | Cincinnati | Ohio | 45219 | — |
| Pfizer Investigational Site | Cincinnati | Ohio | 45267 | — |
| Pfizer Investigational Site | Oklahoma City | Oklahoma | 73104 | — |
| Pfizer Investigational Site | Oklahoma City | Oklahoma | 73112 | — |
| Pfizer Investigational Site | Beaver | Pennsylvania | 15009 | — |
| Pfizer Investigational Site | Doylestown | Pennsylvania | 18901 | — |
| Pfizer Investigational Site | Leetsdale | Pennsylvania | 15056 | — |
| Pfizer Investigational Site | Pittsburgh | Pennsylvania | 15212 | — |
| Pfizer Investigational Site | Pittsburgh | Pennsylvania | 15213 | — |
| Pfizer Investigational Site | Cumberland | Rhode Island | 02864 | — |
| Pfizer Investigational Site | Germantown | Tennessee | 38138 | — |
| Pfizer Investigational Site | Knoxville | Tennessee | 37917 | — |
| Pfizer Investigational Site | Dallas | Texas | 75231-7906 | — |
| Pfizer Investigational Site | Dallas | Texas | 75231 | — |
| Pfizer Investigational Site | Plano | Texas | 75024 | — |
| Pfizer Investigational Site | Spokane | Washington | 99204 | — |
| Pfizer Investigational Site | Madison | Wisconsin | 53792 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 256 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00232180, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 21, 2020 · Synced May 16, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00232180 live on ClinicalTrials.gov.